Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td class="align_left">Total numbers</td><td class="align_center">Patients without CIPN</td><td class="align_center" colspan="3">Patients with CIPN</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td class="align_left" rowspan="3">90</td><td class="align_center" rowspan="3">37</td><td class="align_center" colspan="3">53</td></tr><tr><td class="align_center">Grade I</td><td class="align_center">Grade II</td><td class="align_center">Grade III</td></tr><tr><td class="align_center">10</td><td class="align_center">30</td><td class="align_center">13</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>The classification for BC patients with nab-PTX chemotherapy.</div>

BioMed Research International

tab2

Table 2

Table 2: Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer 